Lynchburg Journal of Medical Science

Lynchburg Journal of Medical Science


Family Medicine


Dr. Bernard Toney Jr.


The purpose of this article is to review the efficacy of ivermectin in treating the early stages of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in COVID-19-infected patients. Ivermectin is highly effective against various microorganisms and some viruses. It is proven to treat a wide range of diseases due to its antimicrobial, anti-viral, and anti-cancer properties.1 During the beginning of the COVID-19 pandemic, it was administered globally to treat its early symptoms and prevent further complications from SARS-CoV-2. Few studies have demonstrated the effectiveness of ivermectin in preventing further complications from COVID-19 in low to middle-income countries.2 It was a cost-effective drug used to prevent the spread of COVID-19 in countries that could not provide vaccines to their citizens. Ivermectin is a potential candidate for treating different viruses including COVID-19 during its early stages or as prevention due to its antiviral properties.1 Although multiple countries have used ivermectin to treat and protect against COVID-19, further research is needed to confirm its safety and efficacy.

Keywords: COVID-19, Ivermectin, Stromectol, SARS-CoV-2, Acute Respiratory Distress Syndrome


Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.

Off-campus users can also use 'Off-campus Download' button above for access.